GlassScriptPhysician profile
Xiaolan Fei
NPI 1548571037
$2,067.41
in general payments reported to CMS, 2019-2025
25 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $87.19 · 2021: $395 · 2022: $510 · 2023: $165 · 2024: $434 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.27 | 2019-2025 | |
| Exeltis, USA INC. | $351.33 | 2019-2025 | Slynd, Nuvessa |
| Pfizer INC. | $147.20 | 2021-2025 | |
| Exact Sciences Corporation | $100.33 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $87.28 | 2021-2025 | Gardasil 9, Gardasil |
| Mayne Pharma Commercial LLC | $76.18 | 2021-2024 | |
| Urovant Sciences INC | $71.84 | 2022 | |
| Sage Therapeutics, LLC | $64.24 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $55.11 | 2019-2020 | |
| Medtronic Vascular, INC. | $53.29 | 2019-2020 | |
| Myovant Sciences INC. | $46.03 | 2022 | |
| Millicent US INC | $36.40 | 2025 | Femlyv, Intrarosa |
| Sumitomo Pharma America, INC. | $35.57 | 2023-2024 | Myfembree, Gemtesa |
| Vertical Pharmaceuticals, LLC | $33.84 | 2019 | |
| Davol INC. | $28.14 | 2025 | Arista |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $27.68 | 2024 | Veozah |
| Boston Scientific Corporation | $23.76 | 2021 | |
| Mission Pharmacal Company | $21.41 | 2021 | |
| Evofem Biosciences, INC. | $20.57 | 2021 | |
| Organon LLC | $20.00 | 2025 | Nexplanon |
| Therapeuticsmd, INC. | $17.64 | 2020 | |
| Coopersurgical, INC. | $16.60 | 2020 | |
| Allergan, INC. | $15.66 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.53 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $15.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaolan Fei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.